




Instance: composition-en-d14c5d7dea1d2e7785c6d37dbbff6788
InstanceOf: CompositionUvEpi
Title: "Composition for orphacol Package Leaflet"
Description:  "Composition for orphacol Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/870/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd14c5d7dea1d2e7785c6d37dbbff6788)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orphacol"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Orphacol is and what it is used for </li>
<li>What you need to know before you take Orphacol </li>
<li>How to take Orphacol </li>
<li>Possible side effects </li>
<li>How to store Orphacol </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orphacol is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orphacol is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orphacol contains cholic acid, a bile acid which is normally produced by the liver. Certain medical 
conditions are caused by defects in bile acid production and Orphacol is used to treat infants from one 
month to 2 years of age, children, adolescents and adults with these medical conditions. The cholic acid 
contained in Orphacol replaces the bile acids that are missing due to the defect in bile acid production. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orphacol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orphacol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Orphacol 
- if you are allergic to cholic acid or any of the other ingredients of this medicine (listed in section 6). 
- if you are taking phenobarbital or primidone, a medicine to treat epilepsy. </p>
<p>Warnings and precautions 
During your treatment, your doctor will carry out various blood and urine tests at different time to see how 
your body is handling this medicine and to help work out the dose that you need. More frequent tests will 
be needed if you are growing fast, if you are ill (if you have e.g. liver problems), or if you are pregnant. </p>
<p>Other medicines and Orphacol 
Tell your doctor or pharmacist if you are taking, have recently taken any or might take other medicines. </p>
<p>Some medicines used to lower cholesterol levels, so-called bile acid sequestrants (cholestyramine, 
colestipol, colesevelam), and medicines to treat heartburn that contain aluminium may lessen the effect of 
Orphacol. If you take these medicines, take Orphacol at least 5 hours before or at least 5 hours after taking 
these other medicines.<br />
Ciclosporin (a medicine used to suppress the immune system) may also change the effect of Orphacol. 
Please tell your doctor if you are taking ciclosporin. 
Ursodeoxycholic acid may lessen the effect Orphacol if both medicines are taken at the same time. 
If you are prescribed ursodeoxycholic acid along with Orphacol in single doses, take one product in the 
morning and the other product in the evening. If you are prescribed divided doses of ursodeoxycholic acid 
and/or Orphacol, as these products should be administered separately by several hours, please ask for the 
advice of your doctor or pharmacist about proper sequence of administration. </p>
<p>Pregnancy and breast-feeding 
Please consult your doctor if you plan to become pregnant. Take a pregnancy test as soon as you suspect 
you may be pregnant. It is very important to continue taking Orphacol during pregnancy. </p>
<p>If you become pregnant during treatment with Orphacol, your doctor will decide which treatment and dose 
is best in your situation. As a precaution, you and your unborn child should be closely monitored during 
pregnancy. </p>
<p>Orphacol can be used during breast-feeding. Tell your doctor if you plan to breast-feed or are breast-
feeding before you take Orphacol. </p>
<p>Ask your doctor or pharmacist for advice before taking any medicine. </p>
<p>Driving and using machines 
Orphacol is not expected to have an effect on the ability to drive and use machines. </p>
<p>Orphacol contains lactose 
Orphacol contains a certain sugar (lactose monohydrate). If you have been told by your doctor that you 
have an intolerance to some sugars, contact your doctor before taking Orphacol. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orphacol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orphacol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take Orphacol exactly as your doctor has told you. Check with your doctor if you are not sure. </p>
<p>The usual starting dose is 5 to 15 mg per kilogram body weight every day in infants, children, adolescents 
and adults. </p>
<p>Before treatment your doctor will make an assessment from your laboratory tests to determine the correct 
dose for you. The dose will then be further adjusted by your doctor depending on your body s response.  </p>
<p>Orphacol capsules are taken by mouth with a meal at approximately the same time each day, in the 
morning and/or evening. Taking Orphacol at regular times with a meal will help you remember to take 
this medicine, and may help your body to better take it up. Capsules must be swallowed whole with water. 
Do not chew. </p>
<p>If your doctor has prescribed a dose which requires you to take more than one capsule per day, you and 
your doctor can decide how this will be taken during the day. You may for example take one capsule in 
the morning and one in the evening. This way, you will have to take fewer capsules at once. However, this 
might not be possible if you have been prescribed at the same time another medicine containing 
ursodeoxycholic acid. In this case, you should seek advice from your doctor or pharmacist about proper 
sequence of administration of ursodeoxycholic acid and Orphacol over the day, as these products should 
be administered separately by several hours (see section 2). 
Use in children 
For babies and children who cannot swallow capsules, the capsule can be opened and its contents added to 
baby formula or apple/orange or apple/apricot juice adapted for small children. </p>
<p>If you take more Orphacol than you should 
If you have taken more Orphacol than you should, contact your doctor as soon as possible. He will assess 
your laboratory test results and advise you when you should resume your treatment with your normal 
dose. </p>
<p>If you forget to take Orphacol 
Take your next dose when you would normally take it. Do not take a double dose to make up for a 
forgotten dose. </p>
<p>If you stop taking Orphacol 
There is a risk of permanently damaging your liver if you stop taking Orphacol. You should never stop 
taking Orphacol unless your doctor advises you to do so. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Several patients have experienced itching and/or diarrhoea, however, it is not known how likely this is to 
occur (frequency cannot be estimated from the available data). If itching and/or diarrhoea last for more 
than three days, tell your doctor. </p>
<p>For several patients an increase of liver enzymes (serum transaminases) have been reported during the 
treatment with Orphacol (frequency cannot be estimated from the available data). Your doctor will decide 
what to do if this happens to you. </p>
<p>Gallstones have been reported after long-term therapy with Orphacol. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By 
reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orphacol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orphacol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep out of the reach and sight of children. </p>
<p>Do not use Orphacol after the expiry date which is stated on the carton and blister after EXP. The expiry 
date refers to the last day of that month. </p>
<p>Store below 30 C. </p>
<p>Medicines should not be disposed of via wasterwater or household waste. Ask your pharmacist how to 
dispose of medicines no longer required. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Orphacol contains<br />
- The active substance is cholic acid.<br />
Orphacol 50 mg: Each hard capsule contains 50 mg of cholic acid. 
Orphacol 250 mg: Each hard capsule contains 250 mg of cholic acid. 
- The other ingredients are: 
Content of capsules: Lactose monohydrate (see section 2 under  Orphacol contains lactose  for 
more information), colloidal anhydrous silica, magnesium stearate 
Capsule shell:<br />
Orphacol 50 mg: gelatin, titanium dioxide (E171), carmine blue (E132); 
Orphacol 250 mg: gelatin, titanium dioxide (E171), carmine blue (E132), yellow iron oxide (E172). </p>
<p>What Orphacol looks like and contents of the pack 
Orphacol is available as hard capsules (capsules) of oblong shape. Capsules of 50 mg cholic acid are blue 
and white and capsules of 250 mg cholic acid are green and white. They are contained in blisters of 
10 capsules each. 
Pack sizes are available in 30, 60 and 120 capsules. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder 
THERAVIA 
16 Rue Montrosier 
92200 Neuilly-sur-Seine 
France </p>
<p>Manufacturer 
THERAVIA 
16 Rue Montrosier 
92200 Neuilly-sur-Seine 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
THERAVIA 
T l/Tel: +32 (0)2 40 11 question@theravia.com   </p>
<p>Lietuva 
Immedica Pharma AB 
Tel/Puh: +46 (0)8 533 39 info@immedica.com </p>
<p>THERAVIA 
Te .: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Luxembourg/Luxemburg 
THERAVIA 
T l/Tel: +352 278 62 question@theravia.com  </p>
<p>esk  republika 
THERAVIA 
Tel.: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Magyarorsz g 
Medis Hungary Kft 
Tel: +36 (2) 380 1info@medis.hu  </p>
<p>Danmark 
Immedica Pharma AB<br />
Tlf: +46 (0)8 533 39 info@immedica.com </p>
<p>Malta 
THERAVIA 
Tel: +356 2776 1question@theravia.com  </p>
<p>Deutschland 
THERAVIA 
Tel: +49 (0)3022153question@theravia.com  </p>
<p>Nederland 
THERAVIA 
Tel: +31 (0)2 070 38 question@theravia.com  </p>
<p>Eesti 
Immedica Pharma AB<br />
Tel/Puh: +46 (0)8 533 39 info@immedica.com  </p>
<p>Norge 
Immedica Pharma AB 
Tel/Puh: +46 (0)8 533 39 info@immedica.com  </p>
<p>THERAVIA 
 : +33 (0)1 72 69 01 question@theravia.com<br />
 sterreich 
THERAVIA 
Tel: +43 (0) 800 909 question@theravia.com  </p>
<p>Espa a 
THERAVIA 
Tel: + (34) 914 146 question@theravia.com  </p>
<p>Polska 
THERAVIA 
Tel.: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>France 
THERAVIA 
T l: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Portugal 
THERAVIA 
Tel: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Hrvatska 
Medis Adria d.o.o. 
Tel: +385 (1) 230 3info@medisadria.hr  </p>
<p>Rom nia 
THERAVIA 
Tel: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Ireland 
THERAVIA 
Tel: +353 (0)1 695 00 question@theravia.com  </p>
<p>Slovenija 
Medis d.o.o. 
Tel: +386 (1) 589 6info@medis.si  </p>
<p>sland 
Immedica Pharma AB 
S mi: + 46 (0)8 533 39 info@immedica.com 
Slovensk  republika 
THERAVIA 
Tel: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Italia 
THERAVIA 
Tel: +39 (0)800 959 question@theravia.com  </p>
<p>Suomi/Finland 
Immedica Pharma AB 
Tel/Puh: +46 (0)8 533 39 info@immedica.com </p>
<p>THERAVIA 
 : +33 (0)1 72 69 01 question@theravia.com </p>
<p>Sverige 
Immedica Pharma AB<br />
Tel: +46 (0)8 533 39 info@immedica.com 
Latvija 
Immedica Pharma AB 
Tel: +46 (0)8 533 39 info@immedica.com 
United Kingdom (Northern Ireland) 
THERAVIA 
Tel: +44 (0)3 301 002 question@theravia.com    </p>
<p>This leaflet was last revised in </p>
<p>This medicine has been authorised under  Exceptional Circumstances . 
This means that because of the rarity of this disease and for ethical reasons it has been impossible to get 
complete information on this medicine. 
The European Medicines Agency will review any new information on the medicine every year and this 
leaflet will be updated as necessary. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-d14c5d7dea1d2e7785c6d37dbbff6788
InstanceOf: CompositionUvEpi
Title: "Composition for orphacol Package Leaflet"
Description:  "Composition for orphacol Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/870/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd14c5d7dea1d2e7785c6d37dbbff6788)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orphacol"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Orphacol 
3. Sådan skal du tage Orphacol 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orphacol is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orphacol is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orphacol indeholder cholsyre, som er en galdesyre, der normalt produceres i leveren. Nogle sygdomme 
skyldes fejl i galdesyreproduktionen, og Orphacol bruges til at behandle spædbørn fra 1 måned til 2 år, 
børn, unge og voksne med disse sygdomme. Cholsyren i Orphacol erstatter de galdesyrer, som mangler på 
grund af fejlen i galdesyreproduktionen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orphacol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orphacol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Orphacol 
- hvis du er allergisk over for cholsyre eller et af de øvrige indholdsstoffer i Orphacol angivet i 
afsnit 6). 
- hvis du tager phenobarbital eller primidon, som er et lægemiddel til behandling af epilepsi. </p>
<p>Advarsler og forsigtighedsregler 
Under din behandling vil din læge tage forskellige blod- og urinprøver på forskellige tidspunkter for at se, 
hvordan din krop reagerer på denne medicin og for at hjælpe med at finde frem til den dosis, du har behov 
for. Der vil blive behov for hyppigere tests, hvis du vokser hurtigt, hvis du er syg (hvis du f.eks. har 
leverproblemer) eller hvis du er gravid.  </p>
<p>Brug af anden medicin sammen med Orphacol 
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt anden 
medicin eller planlægger at bruge anden medicin. </p>
<p>Nogle kolesterolsænkende lægemidler, såkaldte galdesyresekvestranter (cholestyramin, colestipol, 
colesevelam), og lægemidler til behandling af halsbrand, som indeholder aluminium, kan mindske 
Orphacols virkning. Hvis du tager disse lægemidler, skal du tage Orphacol mindst 5 timer før eller mindst 
5 timer efter, at du har taget de andre lægemidler. Ciclosporin (et lægemiddel, som bruges til at 
undertrykke immunsystemet) kan også ændre Orphacols virkning. Fortæl det til lægen, hvis du tager 
ciclosporin. 
Ursodeoxycholinsyre kan nedsætte virkningen af Orphacol, hvis begge lægemidler tages samtidigt. Hvis 
du har fået ordineret ursodeoxycholinsyre sammen med Orphacol i enkeltdoser, skal du tage det ene 
lægemiddel om morgenen og det andet lægemiddel om aftenen. Hvis du har fået ordineret opdelte doser af 
ursodeoxycholinsyre og/eller Orphacol, skal du spørge din læge eller på apoteket, hvad der er det passende 
interval mellem indtagelserne, da der skal være flere timer mellem indtagelsen af det ene og det andet 
lægemiddel. </p>
<p>Graviditet og amning 
Tal med din læge, hvis du har planer om at blive gravid. Tag en graviditetstest, så snart du har mistanke 
om, at du er gravid. Det er meget vigtigt at fortsætte med at tage Orphacol under graviditeten. </p>
<p>Hvis du bliver gravid under behandling med Orphacol, beslutter din læge, hvilken behandling og dosis der 
er bedst i din situation. Som en sikkerhedsforanstaltning skal du og dit ufødte barn overvåges nøje under 
graviditeten. </p>
<p>Orphacol kan anvendes under amning. Fortæl det til lægen, hvis du har planer om at amme eller ammer, 
før du begynder at tage Orphacol. </p>
<p>Spørg din læge eller apotekspersonalet til råds, før du bruger nogen form for medicin. </p>
<p>Trafik- og arbejdssikkerhed 
Orphacol forventes ikke at påvirke evnen til at køre bil eller betjene maskiner. </p>
<p>Orphacol indeholder lactose 
Orphacol indeholder et bestemt sukkerstof (lactosemonohydrat). Kontakt lægen, før du tager Orphacol, 
hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orphacol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orphacol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid Orphacol nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen. </p>
<p>Den sædvanlige startdosis er 5-15 mg pr. kilo legemsvægt hver dag til spædbørn, børn, unge og voksne. </p>
<p>Før behandlingen vurderer din læge dine laboratorieprøver for at se, hvilken dosis der passer til dig. Dosis 
justeres derefter yderligere af din læge, afhængigt af hvordan din krop reagerer på medicinen.  </p>
<p>Orphacol-kapsler tages via munden sammen med et måltid og på omtrent samme tid hver dag, om 
morgenen og/eller om aftenen. Hvis du tager Orphacol regelmæssigt sammen med et måltid, vil det hjælpe 
dig med at huske at tage medicinen, og det kan hjælpe din krop med at optage den bedre. Kapslerne skal 
sluges hele med vand. De må ikke tygges. </p>
<p>Hvis din læge har ordineret en dosis, som kræver, at du tager flere kapsler hver dag, kan du og din læge 
beslutte, hvordan det skal ske i løbet af dagen. Du kan f.eks. tage en kapsel om morgenen og en om 
aftenen. På den måde skal du tage færre kapsler på samme tid. Dette er måske ikke muligt, hvis du 
samtidig har fået ordineret et andet lægemiddel, som indeholder ursodeoxycholinsyre. Hvis dette er </p>
<p>tilfældet, skal du spørge din læge eller på apoteket om, hvad der er det passende interval mellem 
indtagelserne, da der skal være flere timer mellem indtagelsen af det ene og det andet lægemiddel. </p>
<p>Brug til børn 
Til spædbørn og børn, som ikke kan sluge kapsler, kan kapslerne åbnes, og indholdet blandes op i 
modermælkserstatning eller æble/orange- eller æble/abrikosjuice, der er tilpasset til små børn. </p>
<p>Hvis du har taget for mange Orphacol-kapsler 
Hvis du har taget for mange Orphacol-kapsler, skal du henvende dig til din læge så hurtigt som muligt. 
Han vurderer dine laboratorieresultater og rådgiver dig om, hvornår du skal fortsætte behandlingen med 
den normale dosis. </p>
<p>Hvis du har glemt at tage Orphacol 
Tag den næste dosis på det normale tidspunkt. Du må ikke tage en dobbeltdosis som erstatning for den 
glemte dosis. </p>
<p>Hvis du holder op med at tage Orphacol 
Der er risiko for permanent skade på leveren, hvis du holder op med at tage Orphacol. Du må aldrig holde 
op med at tage Orphacol, medmindre lægen siger det. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om vedrørende brugen af denne 
medicin. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Flere patienter har oplevet kløe og/eller diarré, men det vides ikke, hvor sandsynligt det er, at det sker 
(hyppigheden kan ikke estimeres ud fra forhåndenværende data). Hvis kløen og/eller diarréen varer i mere 
end tre dage, skal du fortælle det til lægen. </p>
<p>Der er rapporteret om en stigning i leverenzymer (serum transaminaser) hos flere patienter under 
behandling med Orphacol (hyppigheden kan ikke vurderes ud fra tilgængelige data). Hvis det sker for dig, 
vil din læge beslutte, hvad der skal gøres. </p>
<p>Der er rapporteret om galdesten efter langvarig behandling med Orphacol. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge. Dette gælder også mulige bivirkninger, som ikke 
er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger direkte til 
Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere 
bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orphacol"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orphacol"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar Orphacol utilgængeligt for børn. </p>
<p>Brug ikke Orphacol efter den udløbsdato, der står på pakningen eller blisteren. Udløbsdatoen (Exp) er den 
sidste dag i den nævnte måned. </p>
<p>Opbevares ved temperaturer under 30 °C. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orphacol indeholder:</p>
<ul>
<li>Aktivt stof: cholsyre. </li>
</ul>
<p>Orphacol 50 mg: En hård kapsel indeholder 50 mg cholsyre. </p>
<p>Orphacol 250 mg: En hård kapsel indeholder 250 mg cholsyre. 
- Øvrige indholdsstoffer: 
Kapslens indhold: Lactosemonohydrat (se punkt 2 under ’Orphacol indeholder lactose’ for 
yderligere oplysninger), kolloid vandfri silica, magnesiumstearat </p>
<p>Kapselskal: Orphacol 50 mg: gelatine, titaniumdioxid (E171), Indigotin (E132); </p>
<p>Orphacol 250 mg: gelatine, titaniumdioxid (E171), Indigotin (E132), gul jernoxid (E172). </p>
<p>Udseende og pakningsstørrelser<br />
Orphacol fås som hårde kapsler (kapsler) med aflang form. Kapslerne med 50 mg cholsyre er blå og 
hvide, og kapslerne med 250 mg cholsyre er grønne og hvide. De fås i blisterkort med 10 kapsler i hvert. 
Kapslerne fås i pakningsstørrelser med 30, 60 og 120 kapsler. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen 
THERAVIA 
16 Rue Montrosier 
92200 Neuilly-sur-Seine 
Frankrig </p>
<p>Fremstiller 
THERAVIA 
16 Rue Montrosier 
92200 Neuilly-sur-Seine 
Frankrig </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
THERAVIA 
Tél/Tel: +32 (0)2 40 11 question@theravia.com  </p>
<p>Lietuva 
Immedica Pharma AB 
Tel/Puh: +46 (0)8 533 39 500<br />
info@immedica.com   </p>
<p>България 
THERAVIA 
Teл.: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Luxembourg/Luxemburg 
THERAVIA 
Tél/Tel: +352 278 62 question@theravia.com  </p>
<p>Česká republika 
THERAVIA 
Tel.: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Magyarország 
Medis Hungary Kft 
Tel: +36 (2) 380 1info@medis.hu  </p>
<p>Danmark 
Immedica Pharma AB 
Tlf: +46 (0)8 533 39 500<br />
info@immedica.com  </p>
<p>Malta 
THERAVIA 
Tel: +356 2776 1question@theravia.com  </p>
<p>Deutschland 
THERAVIA 
Tel: +49 (0)3022153question@theravia.com  </p>
<p>Nederland 
THERAVIA 
Tel: +31 (0)2 070 38 question@theravia.com  </p>
<p>Eesti 
Immedica Pharma AB 
Tel/Puh: +46 (0)8 533 39 500<br />
info@immedica.com  </p>
<p>Norge 
Immedica Pharma AB 
Tel/Puh: +46 (0)8 533 39 500<br />
info@immedica.com  </p>
<p>Ελλάδα 
THERAVIA 
Τηλ: +33 (0)1 72 69 01 question@theravia.com<br />
Österreich 
THERAVIA 
Tel: +43 (0) 800 909 question@theravia.com  </p>
<p>España 
THERAVIA 
Tel: + (34) 914 146 question@theravia.com  </p>
<p>Polska 
THERAVIA 
Tel.: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>France 
THERAVIA 
Tél: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Portugal 
THERAVIA 
Tel: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Hrvatska 
Medis Adria d.o.o. 
Tel: +385 (1) 230 3info@medisadria.hr  </p>
<p>România 
THERAVIA 
Tel: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Ireland 
THERAVIA 
Tel: +353 (0)1 695 00 question@theravia.com  </p>
<p>Slovenija 
Medis d.o.o. 
Tel: +386 (1) 589 6info@medis.si  </p>
<p>Ísland 
Immedica Pharma AB 
Sími: + 46 (0)8 533 39 info@immedica.com  </p>
<p>Slovenská republika 
THERAVIA 
Tel: +33 (0)1 72 69 01 question@theravia.com  </p>
<p>Italia 
THERAVIA 
Tel: +39 (0) 800 959 question@theravia.com  </p>
<p>Suomi/Finland 
Immedica Pharma AB 
Tel/Puh: +46 (0)8 533 39 500<br />
info@immedica.com  </p>
<p>Κύπρος 
THERAVIA 
Τηλ: +33 (0)1 72 69 01 question@theravia.com </p>
<p>Sverige 
Immedica Pharma AB 
Tel: +46 (0)8 533 39 500<br />
info@immedica.com 
Latvija 
Immedica Pharma AB 
Tel: +46 (0)8 533 39 500<br />
info@immedica.com  </p>
<p>United Kingdom (Nothern Ireland) 
THERAVIA 
Tel: +44 (0)3 301 002 question@theravia.com  </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Dette lægemiddel er godkendt under "særlige vilkår". 
Det betyder, at det grundet sygdommens sjældenhed og af etiske grunde ikke har været muligt at opnå 
fuldstændig dokumentation for Orphacol. 
Det Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om Orphacol, og denne 
indlægsseddel vil om nødvendigt blive ajourført. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om Orphacol på Det Europæiske Lægemiddelagenturs hjemmeside: 
http://www.ema.europa.eu/. Der er også links til andre websteder om sjældne sygdomme og om, hvordan 
de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-d14c5d7dea1d2e7785c6d37dbbff6788
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orphacol Package Leaflet for language en"
Description: "ePI document Bundle for orphacol Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d14c5d7dea1d2e7785c6d37dbbff6788"
* entry[0].resource = composition-en-d14c5d7dea1d2e7785c6d37dbbff6788

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd14c5d7dea1d2e7785c6d37dbbff6788"
* entry[=].resource = mpd14c5d7dea1d2e7785c6d37dbbff6788
                            
                    
Instance: bundlepackageleaflet-da-d14c5d7dea1d2e7785c6d37dbbff6788
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orphacol Package Leaflet for language da"
Description: "ePI document Bundle for orphacol Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-d14c5d7dea1d2e7785c6d37dbbff6788"
* entry[0].resource = composition-da-d14c5d7dea1d2e7785c6d37dbbff6788

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd14c5d7dea1d2e7785c6d37dbbff6788"
* entry[=].resource = mpd14c5d7dea1d2e7785c6d37dbbff6788
                            
                    



Instance: mpd14c5d7dea1d2e7785c6d37dbbff6788
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Orphacol 50 mg hard capsules"
Description: "Orphacol 50 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/870/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Orphacol 50 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: d14c5d7dea1d2e7785c6d37dbbff6788ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "orphacol"

* status = #current
* mode = #working

* title = "List of all ePIs associated with orphacol"

* subject = Reference(mpd14c5d7dea1d2e7785c6d37dbbff6788)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#orphacol "orphacol"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-d14c5d7dea1d2e7785c6d37dbbff6788) // orphacol en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-d14c5d7dea1d2e7785c6d37dbbff6788) // orphacol da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-d14c5d7dea1d2e7785c6d37dbbff6788
InstanceOf: List

* insert d14c5d7dea1d2e7785c6d37dbbff6788ListRuleset
    